J Thorac Oncol: Final OS analysis of atezolizumab combined with bevacizumab + chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer: IMpower150

Phase III study IMpower150 (NCT02366143) mainly evaluates atezolizumab + bevacizumab + carboplatin + paclitaxel (ABCP) or atezolizumab + carboplatin + paclitaxel (ACP) vs.

Phase III study IMpower150 (NCT02366143) mainly evaluates atezolizumab + bevacizumab + carboplatin + paclitaxel (ABCP) or atezolizumab + carboplatin + paclitaxel (ACP) vs.

Between March 31, 2015 and December 30, 2016, 1202 patients (ITT) were included in the study (all patients used SP142 to detect PD-L1 expression)

Between March 31, 2015 and December 30, 2016, 1202 patients (ITT) were included in the study (all patients used SP142 to detect PD-L1 expression)

In the ITT-WT population, the median OS of the ACP and BCP groups were 19.

Median OS

Among the ITT-WT and ITT populations, the subgroup where ACP has achieved OS benefit over BCP includes men, ECOG PS=0 and a history of smoking

Among the ITT-WT and ITT populations, the subgroup where ACP has achieved OS benefit over BCP includes men, ECOG PS=0 and a history of smoking

When using the SP142 antibody to detect PD-L1 levels, among the patients with high expression of PD-L1 (TC3 or IC3) in the ITT-WT population, the ACP group (median OS=26.

Comparison of high expression OS of SP142 antibody PD-L1

In the SP263 BEP-WT population, among the PD-L1 positive (TC ≥1%) patients assessed with the SP263 antibody, the ACP group (HR 0.

 Comparison of different levels of OS with SP263 antibody PD-L1

SP142 and SP263 antibody evaluation PD-L1 consistency analysis found that 76% of SP142 antibody evaluation PD-L1 positive patients were also PD-L1 positive using SP263 evaluation; while SP263 evaluation PD-L1 positive patients, 75% used SP142 was evaluated as PD-L1 positive
.
76% of patients with high PD-L1 expression evaluated by SP142 were also evaluated as high expression by SP263, while 59% of patients with high PD-L1 expression evaluated by SP263 were evaluated as high expression by SP142
.

SP142 and SP263 antibody evaluation PD-L1 consistency analysis found that 76% of SP142 antibody evaluation PD-L1 positive patients were also PD-L1 positive using SP263 evaluation; while SP263 evaluation PD-L1 positive patients, 75% used SP142 was evaluated as PD-L1 positive
.
76% of patients with high PD-L1 expression evaluated by SP142 were also evaluated as high expression by SP263, while 59% of patients with high PD-L1 expression
evaluated by SP263 were evaluated as high expression by SP142 .
SP142 and SP263 antibody evaluation PD-L1 consistency analysis found that 76% of SP142 antibody evaluation PD-L1 positive patients were also PD-L1 positive using SP263 evaluation; while SP263 evaluation PD-L1 positive patients, 75% used SP142 was evaluated as PD-L1 positive
.
76% of patients with high PD-L1 expression evaluated by SP142 were also evaluated as high expression by SP263, while 59% of patients with high PD-L1 expression evaluated by SP263 were evaluated as high expression by SP142
.

Comparison of the consistency of the two antibody PD-L1 levels

Comparison of the consistency of the two antibody PD-L1 levels

Treatment-related adverse events (AE) occurred in 94.
3%, 94.
1%, and 95.
9% of patients in the ACP, ABCP, and BCP groups, respectively
.
Among them, 43.
0%, 57.
3%, and 49.
0% of patients had grade 3/4 adverse events, respectively
.
The proportions of AEs leading to treatment termination were 14.
5%, 41.
2%, and 26.
4%, respectively
.

Treatment-related adverse events (AE) occurred in 94.
3%, 94.
1%, and 95.
9% of patients in the ACP, ABCP, and BCP groups, respectively
.
Among them, 43.
0%, 57.
3%, and 49.
0% of patients had grade 3/4 adverse events, respectively
.
The proportions of AEs leading to treatment termination were 14.
5%, 41.
2%, and 26.
4%, respectively
.

In summary, the IMpower150 study found that the ACP group improved the patient’s OS numerically compared with the BCP group, but there was no statistical difference; and the updated OS analysis showed that ABCP continued to improve the patient’s OS compared to BCP
.

In summary, the IMpower150 study found that the ACP group improved the patient’s OS numerically compared with the BCP group, but there was no statistical difference; and the updated OS analysis showed that ABCP continued to improve the patient’s OS compared to BCP
.
The IMpower150 study found that the ACP group improved the patient’s OS numerically compared with the BCP group, but there was no statistical difference; and the updated OS analysis showed that ABCP continued to improve the patient’s OS compared to BCP
.
The IMpower150 study found that the ACP group improved the patient’s OS numerically compared with the BCP group, but there was no statistical difference; and the updated OS analysis showed that ABCP continued to improve the patient’s OS compared to BCP
.

Original source:

Original source:

Mark A.
Socinski, Makoto Nishio, Robert M.
Jotte, et al.
IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer.
Journal of Thoracic Oncology.
DOI: https:/ /doi.
org/10.
1016/j.
jtho.
2021.
07.
009.

Mark A.
Socinski, Makoto Nishio, Robert M.
Jotte, et al.
IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer.
Journal of Thoracic Oncology.
DOI: https:/ /doi.
org/10.
1016/j.
jtho.
2021.
07.
009.


Leave a message here